Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
about
Heparin for the prevention of intraventricular haemorrhage in preterm infantsPentasaccharides for the treatment of deep vein thrombosisHeparin for the prevention of intraventricular hemorrhage in very preterm infantsHeparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesHeparin: Past, Present, and FutureThe evolution of anticoagulant therapyPrevention of venous thromboembolism in patients undergoing bariatric surgeryObesity: physiologic changes and implications for preoperative managementMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewThromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)What is the Best Treatment for a Cancer Patient with Thrombosis?The emergent reversal of coagulopathies encountered in neurosurgery and neurology: a technical noteGuidance for the practical management of warfarin therapy in the treatment of venous thromboembolismPharmacology of anticoagulants used in the treatment of venous thromboembolismGuidance for the treatment of deep vein thrombosis and pulmonary embolismGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismEvaluation of 2 nomogram-based strategies for dosing argatroban in patients with known or suspected heparin-induced thrombocytopenia.Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.Heparin induced thrombocytopenia: review.An approach to heparin and lidocaine hypersensitivity for the interventional nephrologist.Successful use of fondaparinux early after mechanical aortic valve replacement in a patient with a history of heparin-induced thrombocytopenia.A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients.Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failureFondaparinux Monitoring: Need for a Local Fondaparinux-Calibrated Anti-F actor Xa Assay.Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type IIClinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy.Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.Anticoagulation Therapy in Patients with Chronic Kidney Disease.Direct Thrombin Inhibitor Resistance and Possible Mechanisms.Preliminary data on utility of subcutaneous unfractionated heparin in patients with deep cerebral venous thrombosis.The safety profile of preoperative administration of heparin for thromboprophylaxis in Chinese patients intended for thoracoscopic major thoracic surgery: a pilot randomized controlled studyPerioperative management of patients on direct oral anticoagulants.The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.Cancer-associated thrombosis: an overviewMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.
P2860
Q24185786-9B8656E4-D493-4636-BD6D-DAA81851EEEDQ24186811-C13E8325-877E-4C0B-BDC9-80157780E62BQ24188179-61424E16-DCD4-4871-B899-46A2433E447BQ24194750-65958FA6-08D4-4984-BF73-60DA1EA1A388Q24632982-F06AF336-E4BC-4A6A-8FDC-1698DF404A1CQ24633053-BD278D33-A350-4C3F-95F4-D421A6C5A9E2Q26744227-8BCF156F-892D-4B61-8B44-85AC41609933Q26771859-39C2EF8B-A523-42E6-8830-6A8776626973Q26796429-FA6346B4-C032-464E-A270-706E8736AB6FQ26830911-1A7D349F-5AB5-44E9-B9DC-5E2FA3CBAE2DQ26992262-CFE281F1-4AA1-4005-8B22-29E6D8146B26Q26995284-9BBECC48-0714-4CDF-A640-28CA2A4C4CC6Q27009514-44750509-6463-4955-A761-FEAAC4E5883AQ27014959-7FD1F0CD-1F55-4E3B-B3B3-951C52385ED8Q28066527-6797879C-3A55-428A-BC4F-636384EDE446Q28078967-29ACB58C-D66B-4783-B490-6F15EAFD4A92Q28078989-11B50C5D-90EB-4954-94CF-559AD89ACE0FQ28079081-2CF52533-6788-4C6E-9325-73A4D97FC59EQ33409923-647D91F6-1786-4425-9766-C67C8071C13AQ33409966-1F143EDE-9968-4AC0-888E-BA172EA16A99Q33410083-3C191D7A-EC86-4991-8DC0-7125177D98EDQ33412513-79A4E6EF-BDE5-4817-A09D-07F664CAD7A7Q33414039-5994AA5C-92AD-4ED5-88EA-7656BBA7C699Q33414139-D18459DC-844C-4094-9D7B-8A882ABE9FECQ33414539-E5592AE7-B241-476A-9C3F-A2E641968FF7Q33414541-D35893E4-3FB0-496B-9929-0F13898C5BEDQ33417258-10AAD71F-9BEB-47F5-81F8-38556D6E30C4Q33419371-D36A49F3-BD97-4FA7-B564-223D408E3B5DQ33422300-BA4F4FDC-3E2E-42F5-8EFC-4824E325F4BAQ33433817-EFA52CEF-20D7-461C-AB01-C24BC49CB122Q33435357-76DCC93A-D7D1-4F26-882D-57C7B45E251AQ33438193-99E22388-61CF-4CEE-9DF4-3623240A70F3Q33442728-488AA9EF-A8C4-4107-A706-ED382B0EDBE1Q33639274-7E397857-6150-4EF9-B8C4-74AE7D52FD68Q33692054-11C44232-A9F6-4A23-ADAB-595163C3D0BDQ33763123-E2772395-1C96-4A37-A372-3E67CECFB07CQ34436061-402A35A9-67AD-49FD-AC55-C727D76DA5EBQ34497406-661A4334-E754-42B4-A541-5D7E74EFF819Q34655217-4C085C57-0ED4-4069-B7F5-195C5678DF88Q35154142-66B0D840-56D9-4294-8209-9A2D7CC75EAF
P2860
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@ast
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@en
type
label
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@ast
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@en
prefLabel
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@ast
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@en
P2093
P2860
P356
P1433
P1476
Parenteral anticoagulants: Ant ...... d Clinical Practice Guidelines
@en
P2093
David A Garcia
Jeffrey I Weitz
Meyer Michel Samama
Trevor P Baglin
P2860
P304
P356
10.1378/CHEST.11-2291
P407
P433
P577
2012-02-01T00:00:00Z